CCA — Cato Certified Associate — Questions and Answers

Question 1: Which study design is considered the gold standard for evaluating the efficacy of a new treatment?

Retrospective cohort study
Single-arm dose-escalation study
Open-label observational study
Randomized double-blind placebo-controlled trial (Correct answer)

Correct answer: Randomized double-blind placebo-controlled trial

The randomized double-blind placebo-controlled trial minimizes bias through randomization, blinding, and a control comparator, making it the gold standard for establishing treatment efficacy.

Question 2: Under GCP, source documents are best defined as:

IRB approval letters
The sponsor's protocol and amendments
Original records and certified copies from which CRF data are transcribed (Correct answer)
The final study database after data cleaning

Correct answer: Original records and certified copies from which CRF data are transcribed

Source documents are the original records (e.g., hospital charts, lab reports) that provide the first-captured data for clinical trial entries.

Question 3: An IRB/IEC must retain its records of approved studies for at least how long after study completion under ICH E6(R2)?

As required by applicable regulations, but no less than 3 years (Correct answer)
5 years
3 years
2 years

Correct answer: As required by applicable regulations, but no less than 3 years

ICH E6(R2) states that IRB/IEC records should be retained as required by applicable regulations, with a general minimum of 3 years post-completion.

Question 4: What is a 'screen failure' in the context of clinical trial enrollment?

A subject who drops out after randomization
A subject who fails to complete all study visits
A randomized subject who does not take the IP
A potential subject who is assessed for eligibility but does not meet inclusion/exclusion criteria and cannot be enrolled (Correct answer)

Correct answer: A potential subject who is assessed for eligibility but does not meet inclusion/exclusion criteria and cannot be enrolled

A screen failure occurs when a potential subject undergoes eligibility screening but does not meet the criteria required for enrollment into the trial.

Question 5: What is 'source data verification' (SDV) in the context of clinical trial monitoring?

Verifying that investigational product shipments match purchase orders
Checking that randomization codes match allocation lists
Comparing data in case report forms against original source documents to check accuracy (Correct answer)
Confirming that electronic data capture systems are validated

Correct answer: Comparing data in case report forms against original source documents to check accuracy

SDV is the process of comparing CRF data against source documents (e.g., medical records, lab reports) to verify accuracy and completeness.

Question 6: In a randomized controlled trial (RCT), what does 'blinding' primarily aim to prevent?

Bias in outcome assessment and participant behavior (Correct answer)
Protocol deviations
Regulatory non-compliance
Participant dropout

Correct answer: Bias in outcome assessment and participant behavior

Blinding prevents knowledge of treatment assignment from influencing participant behavior or outcome assessors' evaluations, thereby reducing bias.

Question 7: What is the purpose of the 'essential documents' checklist used at site initiation?

To reconcile drug inventory
To confirm all required regulatory and administrative documents are in place before enrollment begins (Correct answer)
To track patient recruitment numbers
To schedule monitoring visits

Correct answer: To confirm all required regulatory and administrative documents are in place before enrollment begins

The essential documents checklist ensures all required documents are collected and filed before the site can enroll subjects.

Question 8: Which section of a clinical trial protocol defines the scientific rationale and purpose of the study?

Background and Introduction (Correct answer)
Statistical Analysis Plan
Eligibility Criteria
Administrative Information

Correct answer: Background and Introduction

The Background and Introduction section provides the scientific rationale, prior research, and purpose that justify conducting the study.

Question 9: Under 21 CFR Part 50, a 'short form' written consent document may be used when:

The study involves minimal risk only
Electronic consent is unavailable
The IRB determines that oral presentation of consent elements is appropriate and a witness is present (Correct answer)
The participant is a minor

Correct answer: The IRB determines that oral presentation of consent elements is appropriate and a witness is present

A short form may be used when the IRB approves oral presentation of consent elements to the participant, with a witness signing the document.

Question 10: Under the Trade Agreements Act (TAA), which standard must US government procurement contracts for end products meet?

Products must be manufactured by a US-based company regardless of production location
Products must contain at least 50% US-origin components by value
Products must be manufactured or substantially transformed in the US or a TAA-designated country (Correct answer)
Products must be manufactured or substantially transformed in the US only

Correct answer: Products must be manufactured or substantially transformed in the US or a TAA-designated country

The TAA requires that products purchased under covered US government contracts be either US-made or substantially transformed in a TAA-designated country.

Question 11: In clinical trial operations, what does a 'protocol synopsis' typically contain?

Site feasibility questionnaire responses
A condensed summary of the key elements of the full protocol (Correct answer)
Full statistical analysis plan with all pre-specified endpoints
Regulatory submission cover letters and timelines

Correct answer: A condensed summary of the key elements of the full protocol

A protocol synopsis is a brief summary of the trial's objectives, design, population, endpoints, and key procedures, derived from the full protocol.

Question 12: In clinical trial operations, what does 'SUSAR' stand for?

Suspected Unexpected Serious Adverse Reaction (Correct answer)
Serious Unexpected Safety Alert Report
Standard Unified Safety and Adverse Reaction
Systematic Unexpected Serious Adverse Report

Correct answer: Suspected Unexpected Serious Adverse Reaction

SUSAR stands for Suspected Unexpected Serious Adverse Reaction, requiring expedited reporting to regulatory authorities.

Question 13: Which statistical concept refers to the probability of correctly detecting a true treatment effect if one exists?

Confidence interval
Alpha level
Statistical power (Correct answer)
P-value

Correct answer: Statistical power

Statistical power (1 - beta) is the probability that a trial will detect a true treatment effect of a given size.

Question 14: When reviewing CATO's Top Destinations report, what insight does this provide to an administrator?

The most frequently accessed external IP addresses or domains by users (Correct answer)
Which applications have the highest CPU usage
Which CATO PoPs are handling the most connections
The top users generating the most network traffic

Correct answer: The most frequently accessed external IP addresses or domains by users

The Top Destinations report reveals the most frequently accessed external IP addresses or domains, helping administrators understand user browsing and application usage patterns.

Question 15: What is an adaptive clinical trial design?

A design used exclusively in Phase I studies
A design that uses historical controls instead of a placebo group
A design that allows pre-specified modifications to the trial based on interim data (Correct answer)
A design that does not require randomization

Correct answer: A design that allows pre-specified modifications to the trial based on interim data

Adaptive designs permit pre-specified, data-driven modifications to study parameters (such as sample size or dose) during the trial while maintaining scientific validity and controlling the type I error rate.

Question 16: In CATO's network analytics, what does 'Throughput' measure on a site-level report?

The number of active users connected to the site
The volume of data (bits per second) passing through the site's connection (Correct answer)
The number of security threats blocked at the site
The latency between the site and its nearest PoP

Correct answer: The volume of data (bits per second) passing through the site's connection

Throughput in CATO's site-level reports measures the data transfer rate in bits per second flowing through a site's network connection.

Question 17: What is the difference between 'causality assessment' and 'expectedness' in adverse event reporting?

Causality assesses the relationship of the event to the investigational product; expectedness compares the event to what is described in the reference safety document (Correct answer)
Causality is only assessed by the IRB; expectedness is assessed by the subject
They are the same concept
Expectedness refers to how common the event is in the general population

Correct answer: Causality assesses the relationship of the event to the investigational product; expectedness compares the event to what is described in the reference safety document

Causality determines if the adverse event is related to the IP, while expectedness compares the event to descriptions in the Investigator Brochure or labeling.

Question 18: What is the primary ethical principle that guides subject recruitment in clinical trials?

Maximizing the number of subjects to increase statistical power
Prioritizing subjects with the best insurance coverage
Speed of enrollment
Voluntary participation based on freely given informed consent without coercion (Correct answer)

Correct answer: Voluntary participation based on freely given informed consent without coercion

Voluntary participation based on informed consent without undue influence or coercion is the foundational ethical principle of subject recruitment.

Question 19: What is the primary advantage of using CATO's built-in reporting over exporting logs to an external SIEM?

Built-in reports automatically trigger network policy changes
CATO reports support more data formats than SIEM platforms
Built-in reports provide instant access to pre-correlated SASE data without additional infrastructure (Correct answer)
CATO reports have longer data retention than any SIEM

Correct answer: Built-in reports provide instant access to pre-correlated SASE data without additional infrastructure

CATO's built-in reports offer instant, pre-correlated visibility across SASE components without requiring additional SIEM infrastructure, configuration, or data ingestion pipelines.

Question 20: A subject expresses a desire to withdraw from the clinical trial. What must the investigator do?

Try to persuade the subject to continue by explaining the benefits
Require the subject to provide a written reason before processing the withdrawal
Notify the IRB before allowing the subject to withdraw
Respect the subject's right to withdraw without penalty, ensure safety follow-up as required, and document the withdrawal (Correct answer)

Correct answer: Respect the subject's right to withdraw without penalty, ensure safety follow-up as required, and document the withdrawal

Subjects have the right to withdraw at any time without penalty; the investigator must respect this, ensure safety follow-up, and document the reason if provided.

Question 21: How long must clinical trial records typically be retained at the investigative site under FDA regulations?

5 years from the last subject's last visit
2 years after the latest marketing application is approved, or 2 years after the IND is withdrawn (per 21 CFR 312.62) (Correct answer)
1 year after trial completion
Indefinitely

Correct answer: 2 years after the latest marketing application is approved, or 2 years after the IND is withdrawn (per 21 CFR 312.62)

Under 21 CFR 312.62, investigators must retain records for 2 years following the date a marketing application is approved, or 2 years after the IND is discontinued.

Question 22: Which of the following actions constitutes 'gross negligence' under CBP's penalty statute (19 USC 1592)?

An isolated clerical error on a commercial invoice
Failure to file entry documents within the 15-day free time period
An act or omission done with actual knowledge of or wanton disregard for relevant facts and a reckless disregard for legal obligations (Correct answer)
Using an incorrect country of origin on a label due to a supplier error

Correct answer: An act or omission done with actual knowledge of or wanton disregard for relevant facts and a reckless disregard for legal obligations

Under 19 USC 1592, gross negligence is defined as an act or omission that results from an indifference to or reckless disregard for relevant facts and a reckless disregard for legal obligations.

Question 23: After a clinical trial is closed, for how long should informed consent forms be retained under FDA regulations?

Until the subject's death
1 year
6 months
Per the general record retention timeline—2 years after marketing approval or IND discontinuation (or longer per sponsor instructions) (Correct answer)

Correct answer: Per the general record retention timeline—2 years after marketing approval or IND discontinuation (or longer per sponsor instructions)

Informed consent forms follow the same FDA retention timeline as other trial records—at minimum 2 years post-marketing approval or IND discontinuation, unless the sponsor specifies longer.

Question 24: What is the term for a subject who cannot be located for follow-up visits or safety assessments?

Non-compliant subject
Screen failure
Protocol violator
Lost to follow-up (LTFU) (Correct answer)

Correct answer: Lost to follow-up (LTFU)

A subject who cannot be contacted or located for required follow-up is classified as 'lost to follow-up' (LTFU), which must be documented and reported.

Question 25: What is the primary purpose of a site close-out visit (COV) in a clinical trial?

To ensure all study activities are complete, IP is reconciled and returned/destroyed, data queries resolved, and essential documents are in order for archiving (Correct answer)
To train staff on the next study
To randomize remaining subjects
To conduct the final safety review of SAEs

Correct answer: To ensure all study activities are complete, IP is reconciled and returned/destroyed, data queries resolved, and essential documents are in order for archiving

The COV confirms that all trial activities have been completed, IP accounted for, data finalized, and documents are ready for archiving per sponsor and regulatory requirements.

Question 26: Which of the following is TRUE regarding the destruction of unused investigational product?

Destruction certificates are optional if the PI signs a statement
IP must be destroyed only after sponsor authorization and per local regulations, with documentation (Correct answer)
IP is always returned to the sponsor; on-site destruction is never permitted
Sites may destroy IP at their own discretion after trial completion

Correct answer: IP must be destroyed only after sponsor authorization and per local regulations, with documentation

IP destruction requires written sponsor authorization, must comply with local regulations, and must be documented with a destruction certificate.

Question 27: What role does an Institutional Review Board (IRB) play in clinical research?

It manages site staff
It protects participants' rights and safety (Correct answer)
It writes scientific publications
It oversees funding

Correct answer: It protects participants' rights and safety

The IRB reviews and approves study protocols to ensure ethical treatment of participants.

Question 28: In a clinical trial, what is a 'comparator product'?

A product used only after unblinding
The backup supply held at the sponsor's warehouse
An approved or investigational product used as a reference in a controlled trial for comparison with the investigational product (Correct answer)
A placebo tablet used only in Phase I trials

Correct answer: An approved or investigational product used as a reference in a controlled trial for comparison with the investigational product

A comparator product is an approved or investigational agent used as a control against which the investigational product's effects are compared.

Question 29: When a clinical site receives a shipment of investigational product, what should be done first?

Immediately dispense to the next eligible subject
Inspect the shipment, verify contents against the packing list, and check storage conditions were maintained during transit (Correct answer)
Enter the receipt in the CRF
Notify the IRB of the new supply

Correct answer: Inspect the shipment, verify contents against the packing list, and check storage conditions were maintained during transit

Upon IP receipt, the site must inspect the shipment for damage, verify quantities against the packing list, and confirm transit temperature logs before accepting the product.

Question 30: What document accompanies each shipment of investigational product (IP) to a clinical site?

IRB approval letter
Protocol synopsis
Delegation log
Drug shipment manifest / packing slip (Correct answer)

Correct answer: Drug shipment manifest / packing slip

A drug shipment manifest or packing slip accompanies each IP shipment to verify contents, quantities, and storage conditions.

Question 31: Which form must be submitted to the FDA before beginning a clinical trial?

Protocol deviation form
Form 1572
IND application (Correct answer)
Site startup checklist

Correct answer: IND application

The Investigational New Drug (IND) application must be submitted and approved before human testing can begin.

CCA — Cato Certified Associate

The CCA (Cato Certified Associate) exam validates foundational knowledge of clinical trial operations, GCP compliance, regulatory requirements, investigational product management, and study design for professionals entering clinical research.

Questions

35 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds